** Orthocell jumps as much as 21.1% to A$0.775, highest since May 9, 2019
** Stock logs biggest intraday pct jump since early October
** Biotech firm signs distributorship agreement with Singapore-based Device Technologies Asia for exclusive distribution of its nerve repair device Remplir
** OCC expects first sales of the device in first quarter of 2025
** Around 2.3 mln shares traded, 3.2x the 30-day avg
** Stock up ~87% YTD
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。